flow trial semaglutide results Long-term kidney outcomes of in obesity and cardiovascular disease in the SELECT The FLOW trial for semaglutide

Description

Also, a small cross-sectional study of 36 women with PCOS noted no changes in depression scores associated with liraglutide use over 6 months 204 , while another reported worsening depressive symptoms, which correlated with higher perceived stress scores, in 43 exenatide users with diabetes and obesity against non-users at 3 months 205

Semaglutide is an analogue of native GLP-1 with a prolonged half-life (165 h), suitable for administration once a week (ow)

Request an appointment and choose telehealth or in-person

Separate-vial users need two vials per cycle phase (retatrutide + cagrilintide)

Jiang Y, Wang L, Dong Z, Xia B, Pang S (2024) Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat Type 2 diabetes: a review study